Published December 24, 2004 | Version v1
Journal article

Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1)

  • 1. Centre for Oxygen, Research and Development (C.O.R.D.), Institut de Chimie, B6a, University of Liege, Sart Tilman, 4000 Liege (Belgium)
  • 2. Department of Anaesthesia and Intensive Care, University Hospital of Liege (Belgium)
  • 3. Natural and Synthetic Drug Research Centre, University of Liege (Belgium)
  • 4. Bioenergetics Laboratory, University of Liege (Belgium)
  • 5. Biomedical Spectroscopy Laboratory, University of Liege (Belgium)

Description

Chronic inflammation through foam cells and macrophages is important in atherosclerosis development, and can be considered as therapeutic targets. Cyclooxygenase and NADPH-oxidase were expressed within atherosclerotic lesions. Reactive oxygen species produced by NADPH oxidase were found to trigger the cyclooxygenase-2 expression. The effects of preferential COX-2 inhibitors on ROS produced by Chlamydia-primed human monocytes (THP-1 cells) were evaluated by fluorescence, chemiluminescence, oxymetry, and EPR spin trapping. Fluorescence assays showed an increased production of ROS with Chlamydia versus cells primed by 10-8 M PMA. COX-2 inhibitors inhibited in a dose-dependent manner the luminol-enhanced CL while ibuprofen and diclofenac increased the chemiluminescence response. By EPR spin trapping, COX-2 inhibitors, ibuprofen, and diclofenac, exhibited a dose-dependent inhibiting effect (10 and 100 μM) on the EPR signal appearance. Our cell model combining EPR, chemiluminescence, and oxymetry appeared relevant to study the modulating effects of preferential COX-2 inhibitors on the cell oxidant activity and chronic inflammatory diseases

Additional details

Identifiers

DOI
10.1016/j.bbrc.2004.10.155;
PII
S0006-291X(04)02447-7;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
325
Journal Issue
4
Journal Page Range
p. 1122-1130
ISSN
0006-291X
CODEN
BBRCA9

Optional Information

Copyright
Copyright (c) 2004 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.